- Moderna's RSV vaccine, mRESVIA, now FDA-approved for adults aged 18-59 at higher risk.
- Wall Street analysts' average price target suggests a potential 71.30% upside.
- Current brokerage consensus: Hold, with a GF Value downside estimate of 25.41%.
Moderna Inc. (MRNA) has taken another significant step in the pharmaceutical landscape with the FDA's approval of its RSV vaccine, mRESVIA (mRNA-1345). This approval extends its applicability to adults aged 18-59 who are at elevated risk of respiratory diseases, further building on its earlier approval for individuals aged 60 and above. As we approach the 2025-2026 respiratory season, this development marks a pivotal moment for the company.
Wall Street Analysts' Insights: Price Targets and Recommendations
Analyzing the forecasts of 20 analysts, the average one-year price target for Moderna Inc (MRNA) is positioned at $46.85. This includes a high estimate of $198.00 and a low of $20.00. The average target indicates a substantial potential upside of 71.30% from the current share price of $27.35. Investors seeking more comprehensive estimate data should visit the Moderna Inc (MRNA, Financial) Forecast page.
The consensus from 26 brokerage firms pegs Moderna Inc's (MRNA) average recommendation at 3.0, suggesting a "Hold" status. This rating uses a scale from 1 to 5, where 1 represents a Strong Buy and 5 signals a Sell.
GF Value Estimation: Assessing the Fair Value
According to estimates from GuruFocus, the GF Value for Moderna Inc (MRNA) over the next year stands at $20.40, indicating a potential downside of 25.41% from the current price of $27.35. The GF Value is GuruFocus' calculated fair value, derived from the stock's historical trading multiples, past growth, and future performance projections. For a more detailed analysis, the Moderna Inc (MRNA, Financial) Summary page provides further insights.
